Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775

Study 309/KEYNOTE‐775 is a phase 3 open‐label, randomized trial of lenvatinib plus pembrolizumab versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer with progression after platinum‐based therapy. Primary endpoints of superiority for lenvatinib plus pembroli...

Descripción completa

Detalles Bibliográficos
Autores principales: Yonemori, Kan, Yunokawa, Mayu, Ushijima, Kimio, Sakata, Jun, Shikama, Ayumi, Minobe, Shinichiro, Usami, Tomoka, Enomoto, Takayuki, Takehara, Kazuhiro, Hasegawa, Kosei, Yamagami, Wataru, Yamamoto, Keiko, Han, Shirong, Dutta, Lea, Orlowski, Robert, Miura, Takuma, Makker, Vicky, Fujiwara, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530883/
https://www.ncbi.nlm.nih.gov/pubmed/35612971
http://dx.doi.org/10.1111/cas.15436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530883/
https://www.ncbi.nlm.nih.gov/pubmed/35612971
http://dx.doi.org/10.1111/cas.15436

Ejemplares similares